retatrutide clinical trials status triumph-3 approval: FDA status, trial results, and when it could be available Study schematics. (A) TRIUMPH‐1, (B) – Phase III retatrutide study demonstrates

What about future retatrutide pricing in 2026 and beyond

Glucagon-like peptide-1 receptor agonist therapy has demonstrated weight loss outcomes averaging 1522% of body weight in clinical trials, making it one of the most effective pharmacological interventions available today

Arthritis Rheum (2008) 58(11):353040

DISCLOSURES: The authors have no conflicts of interest relevant to the contents of this article

systemic disease (lupus, sarcoidosis)

We appreciate commenters' recommendations to reconsider the weightings of the measure groups that contribute to the Overall Hospital Quality Star Rating, implement a customized weighting scheme, or separate out the HAI measures from the Safety of Care measure group